In order to explore how KP alteration in tumor biopsies reflected in the plasma and to further characterize the role of KP in CMM patients, we performed LC-MS/MS metabolite analysis on plasma samples derived from metastatic CMM patients, before (PRE) and during the first treatment (TRM) with MAPKIs (n = 5). This evidence concerns the gene NPPA and neoplasm.